(Press-News.org)
Neurological diseases affect millions worldwide, and the need for long-term patient-friendly treatments has never been greater. While needle-based injections are the standard for most therapies, regular drug injections can often be painful and inconvenient. Microneedles—which are tiny, micron-sized needle systems— have emerged as a promising alternative to conventional needles and offer a pain free way to deliver medicines. However, most existing microneedles are rigid and can cause discomfort during prolonged use and therefore limits their adoption in long-term use.
To overcome this, researchers from South Korea have designed a new microneedles system inspired by the natural mechanism of a bee sting. Led by Professor Wonku Kang and colleague Dr. Sohee Jeon from the College of Pharmacy, Chung-Ang University in collaboration with Dr. Jun-Ho Jeong from College of Medicine at Chung-Ang University, the team introduces wearable “Electrospun Web Microneedle (EW-MNs)” based patches which enable long-term and continuous drug delivery through the skin. The study was made available online in Advanced Healthcare Materials on July 31, 2025.
“Unlike traditional rigid microneedles, which can cause irritation during prolonged use, our EW-MNs are soft, breathable, and remain anchored to the skin just like a bee stinger,” explains Prof. Kang.
To fabricate the EW-MNs, the researchers used an electrospinning process (a technique that uses an electric field to spin very fine polymer fibers) to create a web of nanoscale fibers on metal microneedles. This resulted in a fibrous layer around the microneedle tips which mimic the barbed structure of a bee sting. As a result, the microneedles anchor securely into the skin and ensure a steady attachment for continuous drug release. The EW-MNs were then attached to an adhesive tape and a backing layer to form a patch.
To test the efficacy of the patch, the team loaded the EW-MNs with rivastigmine (a drug commonly used to treat Alzheimer’s and Parkinson’s disease). In animal studies using guinea pigs, the microneedle patches significantly improved the absorption of rivastigmine— releasing over twice the drug and covering a five-fold larger area compared to conventional approaches. Importantly, all this was achieved while maintaining minimum discomfort, and even if any mild skin irritation occurred, it disappeared quickly on removing the patch.
Emphasizing on the impact of this technology, Prof. Kang says “With further development, these EW-MNs could revolutionize drug delivery, allowing patients to receive effective long-term treatments without the fear or discomfort of needles!”
In the future, the team aims to extend the applications of EW-MNs beyond neurological diseases, offering medicated patches for a wide range of other chronic diseases. This approach also holds value for elderly patients, children and cases where safety and patient compliant treatments are urgently needed. Overall, the study demonstrates a perfect example of how nature can drive innovations, bringing us one step closer towards safer, more comfortable, and patient-friendly drug delivery.
***
Reference
DOI: 10.1002/adhm.202501371
About Chung-Ang University
Chung-Ang University is a leading private research university in Seoul, South Korea, dedicated to shaping global leaders for an evolving world. Founded in 1916 and achieving university status in 1953, it combines academic tradition with a strong commitment to innovation. Fully accredited by the Ministry of Education, CAU excels in fields such as pharmacy, medicine, engineering, and applied sciences, driving impactful discoveries and technological progress. Its research-intensive environment fosters collaboration and excellence, producing scholars and professionals who lead in their disciplines. Committed to global engagement, CAU continues to expand its influence as a hub for scientific advancement and future-driven education.
Website: https://neweng.cau.ac.kr/index.do
About Professor Wonku Kang
Dr. Wonku Kang is a Professor at the College of Pharmacy, Chung-Ang University in South Korea. With more than 167 research publications, his research mainly focuses on optimizing drug delivery to target organs and tissues using novel dosage forms and unique concepts. He actively collaborates with researchers and industry partners to develop advanced therapeutic solutions that improve patient outcomes.
Website: https://scholarworks.bwise.kr/cau/researcher-profile?ep=925
END
The Earth’s tropical regions drive some of the most powerful weather and climate variability globally. Among these, the Madden–Julian Oscillation (MJO) is a dominant intraseasonal climate signal, characterized by large clusters of clouds and rainfall that slowly move eastward across the warm tropical oceans. In doing so, the MJO shapes rainfall patterns, influences tropical cyclones, modulates monsoons, and even impacts weather far beyond the tropics. Understanding the factors that govern its ...
Understanding the brain’s functional architecture is a fundamental challenge in neuroscience. The connections between neurons ultimately dictate how information is processed, transmitted, stored, and retrieved, thus forming the basis of our cognitive functions. Scientists often study neuronal signaling by recording the brief electrical pulses they generate over time, often referred to as ‘spike trains.’
Because of their bursty and aperiodic nature, inferring causal relationships between spike trains recorded from different neurons remains ...
(Barcelona, Spain September 9, 2025 1 p.m. CEST / UTC +2) — New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.
The research was presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
SCLC tumors are typically characterized by low expression of major histocompatibility complex class I (MHC-I), which impairs ...
Birds flock in order to forage and move more efficiently. Fish school to avoid predators. And bees swarm to reproduce. Recent advances in artificial intelligence have sought to mimic these natural behaviors as a way to potentially improve search-and-rescue operations or to identify areas of wildfire spread over vast areas—largely through coordinated drone or robotic movements. However, developing a means to control and utilize this type of AI—or “swarm intelligence”—has proved challenging.
In a newly published paper, an international team of scientists describes a framework designed to advance swarm intelligence—by controlling flocking and ...
(Barcelona, Spain--September 9, 2025 at 11:30 AM CEST / UTC +2)— A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).
The results were presented at the International Association for the Study of Lung Cancer at the 2025 World Conference on Lung Cancer (WCLC).
In the fully enrolled Cohort 5 of the PALOMA-2 trial, the Q4W dosing regimen was shown to maintain similar efficacy compared ...
A study led by University of Oxford and Brookhaven National Laboratory researchers has uncovered how exposure to hydrogen atoms dynamically alters the internal structure of stainless steel.
The findings reveal that hydrogen allows internal defects in steel to move in ways not normally possible – which can lead to unexpected failure.
This discovery offers vital insights that could help make hydrogen fuel systems safer and more reliable, from aircraft and fusion reactors to pipelines and storage tanks.
The study has been published today (9 Sept) ...
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).
The research, led by scientists at the National Cancer Center of China, assessed ctDNA in 177 patients with LS-SCLC treated with chemoradiotherapy (CCRT), 77 of whom received consolidation immune checkpoint inhibitors (ICIs). Circulating tumor DNA was measured ...
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) – A new study presented today reports encouraging long-term survival outcomes from an experimental viral immunotherapy, CAN-2409, in patients with advanced non-small cell lung cancer (NSCLC) who previously failed to respond adequately to immune checkpoint inhibitors (ICI).
The study was presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
The phase 2a clinical trial investigated the efficacy of two intratumoral injections of CAN-2409 combined with an oral prodrug (valacyclovir) in ...
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor following EGFR tyrosine kinase inhibitor (TKI) therapy may prolong disease control in patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The trial, which enrolled both oligometastatic and polymetastatic patients, is the first to assess surgical ...
(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A large-scale survey conducted by Lung Cancer Europe (LuCE) has identified critical communication barriers that affect information access, understanding, and shared decision-making among lung cancer patients and caregivers across Europe.
The research was reported at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
The study, based on 2,040 valid survey responses from 34 WHO European Region countries in 20 languages, evaluated three key areas: general knowledge about lung cancer, access to information, ...
